TIDMAMS
RNS Number : 7979T
Advanced Medical Solutions Grp PLC
29 March 2021
29 March 2021
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the surgical and advanced woundcare specialist company , announces
th at it was notified on 25 March 2021 that on the same day Chris
Meredith, who is a Director and PDMR, had sold 10,165 Ordinary
Shares of 5p held on his behalf and 31,125 Ordinary Shares of 5p
held on behalf of his PCAs in the name of Platform Securities
Nominees Limited ("Nominee") at a price of 236.5p per Ordinary
Share.
The Company was also informed that at the same time Individual
Savings Accounts ("ISAs") held in the name of Chris Meredith
purchased 11,800 Ordinary Shares of 5p, a self-invested personal
pension ("SIPP") in the name of Chris Meredith purchased 2,300
Ordinary Shares of 5p, ISAs held in the name of Chris Meredith's
PCAs purchased 21,590 Ordinary Shares of 5p and a self-invested
personal pension ("SIPP") in the name of Chris Meredith's PCAs
purchased 5,600 Ordinary Shares of 5p. All shares were purchased at
a price of 236.53p per Ordinary Share.
The number of shares, and the beneficial ownership of the
shares, held by Chris Meredith and his PCAs remains unchanged.
These transactions are part of normal tax planning.
The transactions are summarised below:
Director Number Price per Number Price paid Number Price paid
of Ordinary Ordinary of Ordinary per Ordinary of Ordinary per Ordinary
Shares Share sold Shares Share by Shares Share by
sold from purchased ISAs purchased a SIPP
Nominee by ISAs by a SIPP
Chris Meredith 33,390 236.5p 33,390 236.53p - -
------------- ------------ ------------- -------------- ------------- --------------
Chris Meredith 7,900 236.5p - - 7,900 236.53p
------------- ------------ ------------- -------------- ------------- --------------
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Chris Meredith
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: Director/PDMR
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name: Advanced Medical Solutions Group plc
---------------------------------------------------------------------
b) LEI: 213800HJP6OWOSZI1L74
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of instrument:
Ordinary Shares of 5p
Identification code: GB0004536594
---------------------------------------------------------------------
b) Nature of the transactions:
* Sale of 33,390 Ordinary Shares of 5p held in the name
of the Nominee
* Purchase of 33,390 Ordinary Shares of 5p by ISAs held
in the name of Chris Meredith or Chris Meredith's
PCAs
---------------------------------------------------------------------
c) Price(s) and volume(s):
Sale of shares: Price(s) Volume(s)
Sale of shares from Nominee
holding at 236.5p per share 33,390
----------
Purchase by ISAs at 236.53p
per share 33,390
----------
---------------------------------------------------------------------
d) Aggregated information: (Relates to those shares sold
only)
Aggregated volume: 33,390
Aggregated price: 236.5p
---------------------------------------------------------------------
e) Date of the transaction: 25/03/2021
---------------------------------------------------------------------
f) Place of the transaction: London Stock Exchange, AIM
Market (XLON)
---------------------------------------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Chris Meredith
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: Director/PDMR
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name: Advanced Medical Solutions Group plc
---------------------------------------------------------------------
b) LEI: 213800HJP6OWOSZI1L74
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of instrument:
Ordinary Shares of 5p
Identification code: GB0004536594
---------------------------------------------------------------------
b) Nature of the transactions:
* Sale of 7,900 Ordinary Shares of 5p held in the name
of the Nominee
* Purchase of 7,900 Ordinary Shares of 5p into a SIPP
held in the name of Chris Meredith or Chris
Meredith's PCAs
---------------------------------------------------------------------
c) Price(s) and volume(s):
Sale of shares: Price(s) Volume(s)
Sale of shares from Nominee
holding at 236.5p per share 7,900
----------
Purchase by a SIPP at 236.53p
per share 7,900
----------
---------------------------------------------------------------------
d) Aggregated information: (Relates to those shares sold
only)
Aggregated volume: 7,900
Aggregated price: 236.5p
---------------------------------------------------------------------
e) Date of the transaction: 25/03/2021
---------------------------------------------------------------------
f) Place of the transaction: London Stock Exchange, AIM
Market (XLON)
---------------------------------------------------------------------
- End -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Olivia AMS@consilium-comms.com
Manser
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence / Patrick
Robb
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, and
internal fixation devices, which it markets under its brands
LiquiBand(R) , RESORBA(R) , and LiquiBandFix8(R) . AMS also
supplies wound care dressings such as silver alginates, alginates
and foams through its ActivHeal(R) brand as well as under white
label. In 2019, the Group made two acquisitions: Sealantis, an
Israeli medical device company with a patent-protected sealant
technology platform; and Biomatlante, an established developer and
manufacturer of innovative surgical biomaterial technologies based
in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a
leading coater and converter of materials predominately for
woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, and the Czech Republic, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has approximately 700 employees. For more information, please see
www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGCGDXUUDDGBC
(END) Dow Jones Newswires
March 29, 2021 06:00 ET (10:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2023 to Apr 2024
